Myriad Genetics Inc MYGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.25
- Day Range
- $4.22–4.44
- 52-Week Range
- $3.53–8.59
- Bid/Ask
- $4.20 / $4.50
- Shares Outstanding
- 94.45M
- Market Cap
- $413.68M
- Volume/Avg
- 876,791 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 3,584.44
- Price/Sales
- 0.49
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 2,700
- Website
- https://www.myriad.com
Valuation
|
Metric
|
MYGN
|
|---|---|
Price/Earnings (Normalized) | 3,584.44 |
Price/Book Value | 1.21 |
Price/Sales | 0.49 |
Price/Cash Flow | 22.67 |
Price/Earnings
MYGN
Financial Strength
|
Metric
|
MYGN
|
|---|---|
Quick Ratio | 1.91 |
Current Ratio | 2.40 |
Interest Coverage | −28.13 |
Quick Ratio
MYGN
Profitability
|
Metric
|
MYGN
|
|---|---|
Return on Assets (Normalized) | 0.09% |
Return on Equity (Normalized) | 0.16% |
Return on Invested Capital (Normalized) | 1.58% |
Return on Assets
MYGN
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Lzcpmrsrz | Rqjv | $174B | |||
| Danaher Corp
DHR
| Nskxftyqj | Pkwn | $127B | |||
| Wuxi AppTec Co Ltd ADR
WUXAY
| — | Ksfklhz | $45B | |||
| Wuxi AppTec Co Ltd
WUXIF
| — | Dbgksw | $45B | |||
| IDEXX Laboratories Inc
IDXX
| Rswnftkq | Lxsl | $44B | |||
| Lonza Group Ltd ADR
LZAGY
| Rmnxcjtbg | Jbjbg | $43B | |||
| Lonza Group Ltd
LZAGF
| — | Yxydzf | $43B | |||
| Agilent Technologies Inc
A
| Czlynwqjs | Tfhxj | $37B | |||
| Waters Corp
WAT
| Zvvxlfy | Jhkp | $35B | |||
| Natera Inc
NTRA
| — | Yfqlqgm | $30B |
United States